CAJ | 학술논문

目的探讨葛根素对肾癌 GRC-1细胞多药耐药的逆转作用.方法体外培养 GRC-1人肾细胞癌株,并分为空白对照组、阿霉素处理组(10 mg·L-1 ADM)、葛根素处理的对照组(0.48 g·L-1 Pur)、阿霉素联合葛根素处理组(10 mg·L-1 ADM+0.24 g·L-1 Pur 或10 mg·L-1 ADM+0.48 g·L-1 Pur),药物处理24 h 后,采用细胞毒性实验检测 GRC-1细胞的生存率,用流式细胞术(Annexin-V/PI 双标记)及 TUNEL 法检测细胞的凋亡情况.结果以对照组细胞生存率为100%,ADM 组细胞生存率为(69.7±0.04)%,显著低于对照组(P<0.05),经0.12、0.24和0.48 g·L-1 Pur 联合用药后,细胞生存率分别为(70.1±0.03)%、(63.2±0.02)%和(42.1±0.04)%,均明显低于空白对照组(P<0.05),且0.24和0.48 g·L-1 Pur 联合用药的细胞生存率显著低于 ADM 处理组(P<0.05);0.12和0.24 g·L-1 Pur 单独用药的细胞生存率分别为(97.4±0.02)%和(90.1±0.01)%,与对照组比较差异无统计学意义(P>0.05),而0.48 g·L-1 Pur 单独用药的细胞生存率为(75.0±0.03)%,显著低于空白对照组(P<0.05).此外,与空白对照组相比,0.24和0.48 g·L-1 Pur 处理细胞后,细胞凋亡率明显升高(P<0.05),且随 Pur 剂量增加而升高;而0.24和0.48 g·L-1 Pur 联合用药组细胞凋亡率均明显高于 ADM 组(P<0.05).结论葛根素可有效促进肾癌 GRC-1细胞的凋亡,并可减轻 GRC-1细胞对阿霉素的耐药性.
목적탐토갈근소대신암 GRC-1세포다약내약적역전작용.방법체외배양 GRC-1인신세포암주,병분위공백대조조、아매소처리조(10 mg·L-1 ADM)、갈근소처리적대조조(0.48 g·L-1 Pur)、아매소연합갈근소처리조(10 mg·L-1 ADM+0.24 g·L-1 Pur 혹10 mg·L-1 ADM+0.48 g·L-1 Pur),약물처리24 h 후,채용세포독성실험검측 GRC-1세포적생존솔,용류식세포술(Annexin-V/PI 쌍표기)급 TUNEL 법검측세포적조망정황.결과이대조조세포생존솔위100%,ADM 조세포생존솔위(69.7±0.04)%,현저저우대조조(P<0.05),경0.12、0.24화0.48 g·L-1 Pur 연합용약후,세포생존솔분별위(70.1±0.03)%、(63.2±0.02)%화(42.1±0.04)%,균명현저우공백대조조(P<0.05),차0.24화0.48 g·L-1 Pur 연합용약적세포생존솔현저저우 ADM 처리조(P<0.05);0.12화0.24 g·L-1 Pur 단독용약적세포생존솔분별위(97.4±0.02)%화(90.1±0.01)%,여대조조비교차이무통계학의의(P>0.05),이0.48 g·L-1 Pur 단독용약적세포생존솔위(75.0±0.03)%,현저저우공백대조조(P<0.05).차외,여공백대조조상비,0.24화0.48 g·L-1 Pur 처리세포후,세포조망솔명현승고(P<0.05),차수 Pur 제량증가이승고;이0.24화0.48 g·L-1 Pur 연합용약조세포조망솔균명현고우 ADM 조(P<0.05).결론갈근소가유효촉진신암 GRC-1세포적조망,병가감경 GRC-1세포대아매소적내약성.
@@@@Objective To investigate the reversal effect of puerarin on mediated multidrug resistance in renal cell carcinoma line GRC-1. Methods GRC-1 cells were cultivated in vitro, and four groups were designed in this experiment: control group, adriamy-cin treatment group with 10 mg·L-1 ADM, puerarin control group with 0.48 g·L-1 Pur, combined treatment group in which 10 mg·L-1 ADM+0.24 g·L-1 Pur or 10 mg·L-1 ADM+0.48 g·L-1 Pur respectively. After treatment with drugs for 24 h,MTT assay was employed to measure cell viability. Flow cytometry with Annexin-V/PI double-labeled) and TUNEL method were used for detecting cell apoptosis. Results Compared with the control group in which the GRC-1 cell viability was 100%, cell viability in ADM group significantly de-creased to (69.7±0.04)% (P<0.05). In the combined treatment group, in which 10 mg·L-1 ADM, combined with 0.12,0.24 and 0.48 g·L-1 Pur was administered to GRC- 1cells, the cell viabilities were (70.1±0.03)%, (63.2±0.02)% and (42.1±0.04)% respectively, which were obviously lower than that in the control group (P<0.05), The cells viabilities of two subgroups, in which 10 mg·L-1 ADM was com-bined with 0.24 or 0.48 g·L-1 Pur, were much lower than that in the ADM group(P<0.05). The cell viabilities of the only 0.12 g·L-1 or 0.24 g·L-1 Pur treated group were respectively (97.4±0.02)% and (90.1±0.01)%, having no significant difference from the control group (P>0.05). But after treated by 0.48 g·L-1 Pur alone, the cell viability was (75.0±0.03)%, much lower than that in the control group (P<0.05). Compared with the control group, the apoptotic rates of GRC-1cells in 0.24 and 0.48 g·L-1 puerarin groups significantly in-creased in a dose-dependent manner (P<0.05). The apoptotic rates of 10 mg·L-1 adriamycin plus 0.24 g·L-1 puerarin or 0.48 g·L-1 puer-arin groups were remarkablely higher than that of the ADM group (P<0.05). Conclusion Puerarin may effectively promote the apoptosis of GRC-1 cells and increase the anticarcinogenic effect of adriamycin by reversing multidrug resistance in GRC-1 cells.